Drug repositioning by merging active subnetworks validated in cancer and COVID-19
Abstract Computational drug repositioning aims at ranking and selecting existing drugs for novel diseases or novel use in old diseases. In silico drug screening has the potential for speeding up considerably the shortlisting of promising candidates in response to outbreaks of diseases such as COVID-...
Guardado en:
Autores principales: | Marta Lucchetta, Marco Pellegrini |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f24d7a8f817543edb45cc29d3711cbed |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Transcriptomics-based drug repositioning pipeline identifies therapeutic candidates for COVID-19
por: Brian L. Le, et al.
Publicado: (2021) -
Identification of significantly mutated subnetworks in the breast cancer genome
por: Rasif Ajwad, et al.
Publicado: (2021) -
Evaluation of connectivity map shows limited reproducibility in drug repositioning
por: Nathaniel Lim, et al.
Publicado: (2021) -
Computational repositioning and preclinical validation of mifepristone for human vestibular schwannoma
por: Jessica E. Sagers, et al.
Publicado: (2018) -
Drug repositioning of Clopidogrel or Triamterene to inhibit influenza virus replication in vitro.
por: Nichole Orr-Burks, et al.
Publicado: (2021)